TY - JOUR
T1 - Tissue factor expression in ovarian cancer
T2 - Implications for immunotherapy with hI-con1, a factor VII-IgGF c chimeric protein targeting tissue factor
AU - Cocco, Emiliano
AU - Varughese, Joyce
AU - Buza, Natalia
AU - Bellone, Stefania
AU - Lin, Ken Yu
AU - Bellone, Marta
AU - Todeschini, Paola
AU - Silasi, Dan Arin
AU - Azodi, Masoud
AU - Schwartz, Peter E.
AU - Rutherford, Thomas J.
AU - Carrara, Luisa
AU - Tassi, Renata
AU - Pecorelli, Sergio
AU - Lockwood, Charles J.
AU - Santin, Alessandro D.
N1 - Funding Information:
Acknowledgments Supported in part by grants from NIH R01 CA122728-01A2 to AS, and grants 501/A3/3 and 0027557 from the Italian Institute of Health (ISS) to AS. This investigation was also supported by NIH Research Grant CA-16359 from the National Cancer Institute. The Authors thank Dr. William Konigsberg, Dr. Alan Garen and Dr. Zhiwei Hu for initiating the collaboration with CJL on Icon immunotherapy of human gynecologic malignancies and Iconic Therapeutics Inc. for providing hI-con1 protein free of charge for our studies.
PY - 2011/10
Y1 - 2011/10
N2 - We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. We studied the expression of TF in 88 EOC by immunohistochemistry (IHC) and real-time-PCR (qRT-PCR) and the levels of membrane-bound-complement-regulatory-proteins CD46, CD55 and CD59 in primary EOC cell lines by flow-cytometry. Sensitivity to hI-con1-dependent-cell-mediated-cytotoxicity (IDCC), complement-dependent-cell- cytotoxicity and inhibition of IDCC by γ-immunoglobulin were evaluated in 5-h 51chromium-release-assays. Cytoplasmic and/or membrane TF expression was observed in 24 out of 25 (96%) of the EOC samples tested by IHC, but not in normal ovarian-tissue. EOC with clear cell histology significantly overexpress TF when compared to serous, endometrioid, or undifferentiated tumors by qRT-PCR. With a single exception, all primary EOC that overexpressed TF demonstrated high levels of CD46, CD55 and CD59 and regardless of their histology or resistance to chemotherapy, were highly sensitive to IDCC. The effect of complement and physiologic doses of γ-immunoglobulin on IDCC in ovarian cancer cell lines overexpressing TF was tumor specific and related to the overexpression of CD59 on tumor cells. Small-interfering-RNA-mediated knockdown of CD59 expression in ovarian tumors significantly increased hI-con1-mediated cytotoxic activity in vitro. Finally, low doses of interleukin-2 further increased the cytotoxic effect induced by hI-con1 (P < 0.01). hI-con1 molecule induces strong cytotoxicity against primary chemotherapy-resistant ovarian cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of ovarian tumors refractory to standard treatment modalities.
AB - We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. We studied the expression of TF in 88 EOC by immunohistochemistry (IHC) and real-time-PCR (qRT-PCR) and the levels of membrane-bound-complement-regulatory-proteins CD46, CD55 and CD59 in primary EOC cell lines by flow-cytometry. Sensitivity to hI-con1-dependent-cell-mediated-cytotoxicity (IDCC), complement-dependent-cell- cytotoxicity and inhibition of IDCC by γ-immunoglobulin were evaluated in 5-h 51chromium-release-assays. Cytoplasmic and/or membrane TF expression was observed in 24 out of 25 (96%) of the EOC samples tested by IHC, but not in normal ovarian-tissue. EOC with clear cell histology significantly overexpress TF when compared to serous, endometrioid, or undifferentiated tumors by qRT-PCR. With a single exception, all primary EOC that overexpressed TF demonstrated high levels of CD46, CD55 and CD59 and regardless of their histology or resistance to chemotherapy, were highly sensitive to IDCC. The effect of complement and physiologic doses of γ-immunoglobulin on IDCC in ovarian cancer cell lines overexpressing TF was tumor specific and related to the overexpression of CD59 on tumor cells. Small-interfering-RNA-mediated knockdown of CD59 expression in ovarian tumors significantly increased hI-con1-mediated cytotoxic activity in vitro. Finally, low doses of interleukin-2 further increased the cytotoxic effect induced by hI-con1 (P < 0.01). hI-con1 molecule induces strong cytotoxicity against primary chemotherapy-resistant ovarian cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of ovarian tumors refractory to standard treatment modalities.
KW - Cancer
KW - Factor VII
KW - Immunotherapy
KW - Ovarian carcinoma
KW - Tissue factor
UR - http://www.scopus.com/inward/record.url?scp=82355182088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82355182088&partnerID=8YFLogxK
U2 - 10.1007/s10585-011-9401-0
DO - 10.1007/s10585-011-9401-0
M3 - Article
C2 - 21725665
AN - SCOPUS:82355182088
SN - 0262-0898
VL - 28
SP - 689
EP - 700
JO - Clinical and Experimental Metastasis
JF - Clinical and Experimental Metastasis
IS - 7
ER -